Antiretroviral therapy (ART) for HIV is a lifelong treatment. There is no point in the course of HIV management where stopping ARVs is medically recommended, regardless of how well the treatment is working or how healthy you feel. The World Health Organization recommends ART for all people living with HIV, started as soon as possible after diagnosis, with no planned endpoint.
That said, the question is understandable. When your viral load is undetectable and you feel completely healthy, it’s natural to wonder whether the medication is still necessary. Here’s what happens biologically when ARVs are stopped, why guidelines are firm on this, and how ART differs from other HIV-related medications that do have a stopping point.
What Happens When You Stop ARVs
HIV doesn’t leave your body when treatment suppresses it. The virus hides in long-lived immune cells, forming what researchers call a “viral reservoir.” ART keeps the virus from replicating, but the moment that suppression is removed, HIV begins copying itself again. In a study published in Clinical Infectious Diseases, the median time to significant viral rebound after stopping modern ART was just 22 days. Some people rebounded in as few as 13 days.
Once the virus is replicating freely, your immune system takes the hit. Without treatment, CD4 cells (the white blood cells HIV targets) decline at an estimated rate of about 50 cells per year on average, though this varies widely between individuals. Over time, that decline opens the door to opportunistic infections and AIDS-defining illnesses that ART was preventing.
Viral rebound can also cause physical symptoms similar to what people experience during initial HIV infection: fever, fatigue, sore throat, swollen lymph nodes, rash, weight loss, and night sweats. These symptoms can appear within two weeks of stopping treatment.
The Largest Trial on Treatment Interruption
The strongest evidence against stopping ARVs comes from a major clinical trial called the SMART study, published in the New England Journal of Medicine. The trial enrolled over 5,000 participants and compared continuous ART against a strategy of pausing treatment when CD4 counts were high and restarting when they dropped.
The results were so clear the trial was stopped early. Participants who took breaks from treatment were 2.6 times more likely to develop opportunistic infections or die from any cause compared to those who stayed on continuous therapy. They also had 1.7 times the risk of serious cardiovascular, kidney, and liver disease. The findings surprised researchers because the organ damage wasn’t just from the virus attacking the immune system. Uncontrolled HIV also drives chronic inflammation throughout the body, damaging blood vessels and organs even before CD4 counts drop to dangerous levels.
Drug Resistance: A Lasting Consequence
Stopping and restarting ARVs creates an environment where drug-resistant strains of HIV can emerge. When the virus replicates in the presence of inconsistent drug levels (as happens during the days around stopping or restarting), mutations can develop that make specific medications less effective or completely useless. Even occasionally skipping doses increases this risk.
Drug resistance is not reversible. If your virus develops resistance to a particular class of medication, that class may no longer be an option for you, narrowing your future treatment choices. This is one of the strongest practical arguments against treatment interruptions: even if you plan to restart later, you may find that your previous regimen no longer works.
What About Elite Controllers?
A very small number of people living with HIV, sometimes called elite controllers, naturally suppress the virus to extremely low levels without medication. You might wonder whether they can safely skip ART. The answer is complicated but leans toward treatment.
Major guidelines from organizations like the U.S. Department of Health and Human Services don’t make a firm recommendation either way for elite controllers with high CD4 counts. However, lab studies have shown that even in these individuals, markers of inflammation, immune activation, and hidden viral activity improve after starting ART. There’s also evidence that waiting to start treatment until CD4 cells have already declined may blunt the immune system’s ability to recover. For almost everyone, including most elite controllers, the safest path is staying on treatment.
PrEP and PEP Are Different
If your search brought you here because you’re taking HIV prevention medication rather than treatment, the rules are very different. PrEP (pre-exposure prophylaxis) and PEP (post-exposure prophylaxis) are both designed to be stopped under specific conditions.
Stopping PrEP
PrEP is for people who are HIV-negative and at elevated risk of exposure. You can stop PrEP when the circumstances that put you at risk are no longer present and that change is likely to last. The WHO recommends continuing PrEP for 28 days after your last potential exposure. CDC guidelines suggest a shorter window of 7 to 10 days after the last exposure. Your provider should document your HIV status and discuss your recent risk factors before discontinuation. The need for PrEP should be reassessed at least every 12 months, and you’ll need a negative HIV test before restarting if you go back on it later.
Stopping PEP
PEP is a 28-day emergency course taken after a potential HIV exposure. You should complete the full 28 days. The one exception: PEP can be stopped early if the source person is confirmed to be HIV-negative at any point during the course. Completing the full course matters because incomplete PEP may not prevent infection, and if infection does occur despite partial treatment, it increases the chance of drug-resistant HIV.
When Doctors Supervise a Treatment Pause
Structured treatment interruptions, where a doctor deliberately pauses ART under close monitoring, do exist but only within controlled clinical trials. These trials are exploring whether specific interventions (like therapeutic vaccines or drugs targeting the viral reservoir) can allow even temporary control of HIV without daily medication. Outside of a clinical trial, no medical guidelines support pausing ART for any reason, including side effects or feeling well.
If side effects are making your current regimen difficult to tolerate, switching to a different combination of ARVs is the standard approach. Modern regimens are simpler and better tolerated than older ones, often requiring just one pill per day. Talking to your provider about switching medications is a far safer path than stopping treatment altogether.